EO1001

EO1001 (also known as APL-122) is a first-in-class, oral, irreversible pan-ErbB tyrosine kinase inhibitor developed for the treatment of advanced solid tumors. It targets multiple members of the ErbB receptor family—specifically Epidermal growth factor receptor (EGFR), Receptor protein-tyrosine kinase erbB-2 (HER2), and Receptor protein-tyrosine kinase erbB-4 (HER4)—and has demonstrated potent inhibition against these receptors in preclinical studies. Notably, EO1001 is designed to penetrate the central nervous system and has shown activity against both intracellular and extracellular domain mutations of Epidermal growth factor receptor that are commonly found in non-small cell lung cancer and glioblastoma. The drug is being evaluated in Phase 1/2 clinical trials for patients with ErbB-positive cancers who have progressed after standard therapies, including those with CNS involvement. Preclinical data indicate a favorable pharmacokinetic profile and tolerability[1][4][5][6].

Other names

EO1001EO-1001EO 1001